Published in Adv Urol on July 02, 2012
Gene microarray analysis of the lncRNA expression profile in human urothelial carcinoma of the bladder. Int J Clin Exp Med (2014) 0.85
Interaction network analysis of differentially expressed genes and screening of cancer marker in the urine of patients with invasive bladder cancer. Int J Clin Exp Med (2015) 0.80
Urothelial Bladder Cancer Urinary Biomarkers. EJIFCC (2014) 0.76
Biomarkers for non-muscle invasive bladder cancer: Current tests and future promise. Indian J Urol (2015) 0.75
Tumor abnormal protein (TAP) examination contributes to primary diagnosis of bladder cancer. Int J Clin Exp Med (2015) 0.75
The Diagnostic Value of Nuclear Matrix Proteins in Bladder Cancer in the Aspect of Environmental Risk from Carcinogens. Biomed Res Int (2017) 0.75
In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction. Proc Natl Acad Sci U S A (1985) 3.42
Nuclear matrix. Isolation and characterization of a framework structure from rat liver nuclei. J Cell Biol (1977) 3.26
CTCF, a conserved nuclear factor required for optimal transcriptional activity of the chicken c-myc gene, is an 11-Zn-finger protein differentially expressed in multiple forms. Mol Cell Biol (1993) 3.08
Ets ternary complex transcription factors. Gene (2004) 2.99
hnRNA and its attachment to a nuclear protein matrix. J Cell Biol (1981) 2.88
Comparison of screening methods in the detection of bladder cancer. J Urol (1999) 2.67
NuMA: an unusually long coiled-coil related protein in the mammalian nucleus. J Cell Biol (1992) 2.33
DNA is replicated at the nuclear cage. J Cell Sci (1980) 2.06
Urine markers for bladder cancer surveillance: a systematic review. Eur Urol (2005) 1.90
Ribonucleic acid precursors are associated with the chick oviduct nuclear matrix. Biochemistry (1982) 1.88
Natural anticoagulant mechanisms. J Clin Invest (1984) 1.75
Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess (2010) 1.62
Dynamic association of replicating DNA fragments with the nuclear matrix of regenerating liver. Exp Cell Res (1981) 1.57
ETS transcription factors: possible targets for cancer therapy. Cancer Sci (2004) 1.52
The many roles of the transcriptional regulator CTCF. Biochem Cell Biol (2003) 1.51
Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res (2003) 1.49
The cell's nucleus shapes up. Science (1993) 1.45
Thrombomodulin-mediated cell adhesion: involvement of its lectin-like domain. J Biol Chem (2003) 1.38
Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J (1995) 1.36
UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur Urol (2006) 1.32
Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology (1998) 1.17
Identification of genes differentially expressed in B16 murine melanoma sublines with different metastatic potentials. Cancer Res (1996) 1.12
Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res (2000) 1.10
Bladder cancer-associated nuclear matrix proteins. Cancer Res (1996) 1.09
Nuclear structural proteins as biomarkers of cancer. J Cell Biochem (1999) 1.08
Retracted Highly specific urine-based marker of bladder cancer. Urology (2005) 1.07
Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer. J Urol (2004) 1.07
Retracted Functional characterization of the bladder cancer marker, BLCA-4. Clin Cancer Res (2004) 1.06
Screening and monitoring for bladder cancer: refining the use of NMP22. J Urol (2001) 1.02
DNA binding properties of the nuclear matrix and individual nuclear matrix proteins. Evidence for salt-resistant DNA binding sites. J Biol Chem (1991) 1.01
Interleukin-8 is essential for normal urothelial cell survival. Am J Physiol Renal Physiol (2009) 0.99
Use of the novel marker BLCA-1 for the detection of bladder cancer. J Urol (2005) 0.98
Retracted Mechanistic analysis of the role of BLCA-4 in bladder cancer pathobiology. Cancer Res (2005) 0.95
Expression of angiogenesis-related genes regulates different steps in the process of tumor growth and metastasis in human urothelial cell carcinoma of the urinary bladder. Pathobiology (2008) 0.94
The discovery of thrombomodulin. J Thromb Haemost (2004) 0.93
Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. J Urol (2002) 0.92
Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression. J Urol (1997) 0.90
IL-8 -251 T > A polymorphism is associated with bladder cancer susceptibility and outcome after BCG immunotherapy in a northern Indian cohort. Arch Med Res (2010) 0.87
Dynamic continuity of nuclear and mitotic matrix proteins in the cell cycle. J Cell Biochem (1996) 0.87
Interleukin-8 (IL-8) over-production and autocrine cell activation are key factors in monomethylarsonous acid [MMA(III)]-induced malignant transformation of urothelial cells. Toxicol Appl Pharmacol (2011) 0.85
Expression of pigment epithelium-derived factor in bladder tumour is correlated with interleukin-8 yet not with interleukin-1α. J Huazhong Univ Sci Technolog Med Sci (2011) 0.84
The management of clinically unconfirmed positive urinary cytology. J Urol (1993) 0.84
Molecular biology of transitional cell carcinoma. Crit Rev Oncol Hematol (2003) 0.84
Dominant genomic structures: detection and potential signal functions in the interferon-beta domain. Gene (2005) 0.84
Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer. Urology (1998) 0.81
Co-localization of poly(ADPR)polymerase 1 (PARP-1) poly(ADPR)polymerase 2 (PARP-2) and related proteins in rat testis nuclear matrix defined by chemical cross-linking. J Cell Biochem (2005) 0.80
Three-year follow-up of bladder tumours found on screening. Br J Urol (1993) 0.80
Nuclear mitotic apparatus protein (NuMA) in benign and malignant diseases. Anticancer Res (1999) 0.79
Utilization of nuclear matrix proteins for cancer diagnosis. Crit Rev Eukaryot Gene Expr (1996) 0.79
Low IL-1alpha expression in bladder cancer tissue and survival. Eur Urol (2003) 0.78
Quanticyt: karyometric analysis of bladder washing for patients with superficial bladder cancer. Urology (1996) 0.77
[Nuclear matrix protein 22 levels in patients with renal transplantation]. Nihon Hinyokika Gakkai Zasshi (1998) 0.76
Analysis of novel metastasis-associated gene TI-227. Jpn J Cancer Res (2000) 0.76
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol (2011) 8.66
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol (2009) 3.48
Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol (2007) 2.24
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol (2007) 2.19
Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones. J Urol (2003) 1.99
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst (2008) 1.92
Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol (2004) 1.64
Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi. J Urol (2005) 1.59
Evidence for the presence of alpha1 adrenoceptor subtypes in the human ureter. Neurourol Urodyn (2005) 1.56
Performance at preoperative stair-climbing test is associated with prognosis after pulmonary resection in stage I non-small cell lung cancer. Ann Thorac Surg (2012) 1.49
Improvement of lower urinary tract symptoms and sexual activity after open simple prostatectomy: prospective analysis of 50 cases. Arch Ital Urol Androl (2014) 1.46
Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor. Eur Urol (2006) 1.45
Tolerability of prostate transrectal biopsies using gel and local anesthetics: results of a randomized clinical trial. J Endourol (2005) 1.43
Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. Int J Cancer (2010) 1.40
Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer (2012) 1.32
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer (2009) 1.31
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. Cancer Treat Rev (2013) 1.26
Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options. Cancer Treat Rev (2010) 1.24
Cystic lesions of the prostate gland: an ultrasound classification with pathological correlation. J Urol (2008) 1.16
Role of maspin in cancer. Clin Transl Med (2013) 1.14
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol (2006) 1.14
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer (2014) 1.11
Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer (2008) 1.10
HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Cancer (2003) 1.10
Solitary fibrous tumour of the prostate identified on needle biopsy. Eur Urol (2009) 1.09
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother (2013) 1.08
Urinary tract infections in women: etiology and treatment options. Int J Gen Med (2011) 1.08
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. BMC Cancer (2014) 1.08
Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. J Exp Clin Cancer Res (2010) 1.07
High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer. Ann Surg Oncol (2014) 1.05
Pancreatic cancer: progress in cancer therapy. Crit Rev Oncol Hematol (2008) 1.04
Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Oncogene (2002) 1.04
FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemother Pharmacol (2012) 1.04
The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. PLoS One (2012) 1.03
Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer. Clin Cancer Res (2004) 1.02
Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. Int J Cancer (2013) 1.01
Progress of molecular targeted therapies for advanced renal cell carcinoma. Biomed Res Int (2013) 1.00
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr Opin Mol Ther (2010) 1.00
Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases. Int J Radiat Oncol Biol Phys (2006) 1.00
Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer. Anticancer Res (2013) 1.00
The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. Expert Opin Investig Drugs (2014) 0.98
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. Oncologist (2011) 0.97
Triggering of transient receptor potential vanilloid type 1 (TRPV1) by capsaicin induces Fas/CD95-mediated apoptosis of urothelial cancer cells in an ATM-dependent manner. Carcinogenesis (2009) 0.97
Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treat Rev (2004) 0.97
Identification of nicotinamide N-methyltransferase as a novel tumor marker for renal clear cell carcinoma. J Urol (2006) 0.96
Upregulation of tissue and urinary nicotinamide N-methyltransferase in bladder cancer: potential for the development of a urine-based diagnostic test. Cell Biochem Biophys (2013) 0.95
Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas. Diagn Cytopathol (2003) 0.95
Altered pattern of cannabinoid type 1 receptor expression in adipose tissue of dysmetabolic and overweight patients. Metabolism (2009) 0.94
Transient receptor potential vanilloid 1 activation induces autophagy in thymocytes through ROS-regulated AMPK and Atg4C pathways. J Leukoc Biol (2012) 0.94
IL-22 mRNA in peripheral blood mononuclear cells from allergic rhinitic and asthmatic pediatric patients. Pediatr Allergy Immunol (2011) 0.93
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. Crit Rev Oncol Hematol (2013) 0.93
5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics (2011) 0.93
Anticandidal immunity and vaginitis: novel opportunities for immune intervention. Infect Immun (2007) 0.93
The transient receptor potential vanilloid-2 cation channel impairs glioblastoma stem-like cell proliferation and promotes differentiation. Int J Cancer (2012) 0.93
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis (2012) 0.92
Expression of transient receptor potential vanilloid-1 (TRPV1) in urothelial cancers of human bladder: relation to clinicopathological and molecular parameters. Histopathology (2010) 0.92
Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis (2012) 0.92
Safety and efficacy of transurethral resection of prostate glands up to 150 ml: a prospective comparative study with 1 year of followup. J Urol (2004) 0.91
Expression pattern alterations of the serine protease HtrA1 in normal human placental tissues and in gestational trophoblastic diseases. Histol Histopathol (2009) 0.91
Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage. Eur Urol (2007) 0.91
Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. J Transl Med (2012) 0.91
Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis. BMC Cancer (2006) 0.90
Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study. Oncology (2007) 0.90
Phenotypic and functional characterization of vaginal dendritic cells in a rat model of Candida albicans vaginitis. Infect Immun (2006) 0.90
Chemotherapy for advanced gastric cancer: across the years for a standard of care. Expert Opin Pharmacother (2007) 0.90
Onabotulinumtoxin-A intradetrusorial injections modulate bladder expression of NGF, TrkA, p75 and TRPV1 in patients with detrusor overactivity. Pharmacol Res (2012) 0.90
Association of thymidylate synthase polymorphisms with gastric cancer susceptibility. Int J Cancer (2004) 0.90
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials. Int J Cancer (2013) 0.89
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. Expert Opin Biol Ther (2014) 0.89
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278). Clin Breast Cancer (2008) 0.89
Essential role of Gli proteins in glioblastoma multiforme. Curr Protein Pept Sci (2013) 0.89
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. Ann Surg Oncol (2014) 0.89
Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. PLoS One (2013) 0.88
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. PLoS One (2013) 0.88
State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. Crit Rev Oncol Hematol (2013) 0.87